JunHe advised the underwriters on the deal, while Fangda, Davis Polk and Conyers advised New Horizon Health Limited.
New Horizon Health Limited issued 76,598,000 shares worldwide (excluding over-allotment) and listed on the Main Board of the Stock Exchange of Hong Kong at a price of HK $26.66 per share, raising more than HKD $2 billion.
New Horizon Health Limited operates cancer screening technology development business.
Goldman Sachs and UBS Securities Co., Ltd. acted as underwriters on the deal.
The JunHe team was led by partners Tiejun Shi (Picture), Xudong Tao and Ruochen Li.
The Fangda team consisted of partners Jeffrey Ding and Diana Li and IP partner Sherry Yao, and other key members included Travis Xu, Siyu Chen, Jeanette Wang, Ziyan Yuan, Emily Xue and Ting Ji.
The Davis Polk corporate team included partners Yang Chu and Howard Zhang, counsel Xuelin (Steve) Wang, registered foreign lawyer Jennifer Liu and associates Lillian Lian, Vivian Chow and Tracy Wu. Counsel Alon Gurfinkel and associate Veronica Davis provided tax advice.
The Conyers team comprised of Partner Christopher Bickley.
Involved fees earner: Christopher Bickley – Conyers Dill & Pearman; Vivian Chow – Davis Polk & Wardwell; Yang Chu – Davis Polk & Wardwell; Veronica Davis – Davis Polk & Wardwell; Alon Gurfinkel – Davis Polk & Wardwell; Lillian Lian – Davis Polk & Wardwell; Jennifer Liu – Davis Polk & Wardwell; Xuelin Wang – Davis Polk & Wardwell; Tracy Wu – Davis Polk & Wardwell; Howard Zhang – Davis Polk & Wardwell; Siyu Chen – Fangda Partners; Jeffrey Ding – Fangda Partners; Ting Ji – Fangda Partners; Diana Li – Fangda Partners; Jeanette Wang – Fangda Partners; Travis Xu – Fangda Partners; Emily Xue – Fangda Partners; Sherry Yao – Fangda Partners; Ziyan Yuan – Fangda Partners; Ruochen Li – Jun He Law Firm; Tiejun Shi – Jun He Law Firm; Xudong Tao – Jun He Law Firm;